Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a
- PDF / 230,351 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 22 Downloads / 169 Views
ORIGINAL ARTICLE
Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study Junying Guo 1 & Zhaolei Cui 1 & Yuhong Zheng 1 & Xiaoli Li 1 & Yan Chen 1 Received: 18 October 2019 / Accepted: 17 March 2020 # Arányi Lajos Foundation 2020
Abstract Epstein-Barr virus (EBV)-based serologic antibody testing has been found to be a feasible alternative for nasopharyngeal carcinoma (NPC) screening in endemic areas. The purpose of this study was to evaluate the performance of ELISA based on VCA IgA antibody, EA-IgA and Rta-IgG antibody specific to EBV in the diagnosis of NPC. A total of 2155 untreated NPC patients and 6957 healthy volunteers without nasopharyngeal disorder were recruited, and all subjects received EBV VCA-IgA, EA-IgA and Rta-IgG antibody tests simultaneously. The diagnostic efficiency of three testing alone or in combination for the diagnosis of NPC was evaluated. The prevalence of IgA antibody against EBV-VCA, IgA antibody against EBV-EA and IgG antibody against EBV-Rta was 89.9%, 46.6% and 63.2%. The sensitivity, specificity, positive predictive value, negative predictive value and Youden index were 89.88%, 89.65%, 73.18%, 96.63% and 0.79 for the EBV VCA-IgA antibody test, 46.59%, 96.89%, 82.5%, 85.42% and 0.43 for the EA-IgA antibody test, and 63.25%, 94.87%, 79.48%, 89.29% and 0.58 for the Rta-IgG antibody test in the diagnosis of NPC, and ROC curve analysis revealed the greatest diagnostic efficiency for EBV VCA-IgA antibody test and the lowest efficiency for EBV EA-IgA antibody test in the diagnosis of NPC. In addition, the simultaneous triple positivity of VCA-IgA, EA-IgA and Rta-IgG antibodies specific to EBV indicated the highest risk of NPC, and the simultaneous triple negativity of the three types of anti-EBV antibodies suggested the lowest risk of NPC. Our data demonstrate that EBV VCA-IgA antibody test shows a higher diagnostic efficiency than EA-IgA and Rta-IgG antibody tests for the screening of NPC, and triple positivity of is a better biomarker for the diagnosis of NPC. Keywords Nasopharyngeal carcinoma . Epstein-Barr virus . VCA-IgA . EA-IgA . Rta-IgG . Serological screening . Diagnostic efficiency . ROC curve analysis
Introduction Nasopharyngeal carcinoma (NPC), the most common cancer originating from the nasopharynx [1], is a rare malignancy worldwide but common in China, notably in southern China [2]. Worldwide, NPC accounted for 0.7% of total new cancer cases and 0.8% of all cancer deaths in 2018 [3]. In China, the new NPC incident cases and deaths were estimated to be 44.6
* Yan Chen [email protected] 1
Department of Clinical Laboratory, Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420 Fuma Road, 350014 Fuzhou City, Fujian Province, China
and 24.2 thousand, and the crude incidence and mortality was 3.26/100000 and 1.77/100000, while the cumulative incidence and mortality was 0.25% and 0.14% in people at ages of 0
Data Loading...
